Clinical Trials Logo

Severe Burn clinical trials

View clinical trials related to Severe Burn.

Filter by:
  • None
  • Page 1

NCT ID: NCT04264065 Recruiting - Severe Burn Clinical Trials

Albumin and Prognosis of Severely Patients Burns

ALBUBURN
Start date: September 16, 2022
Phase:
Study type: Observational

Hemodynamic management has long been identified as a key factor affecting burn prognosis. However, large amounts of crystalloid infusion have been associated with the development or aggravation of organ failure (acute respiratory distress syndrome, vascular injury, acute renal failure, and intra-abdominal hypertension) which worsens the final prognosis. The use of albumin during the first 24 hours of burn resuscitation is controversial since capillary leakage may cause transcapillary passage of large molecules into the interstitial space. In fact, human albumin has multiple physiological effects, including regulation of colloidal osmotic pressure, antioxidant properties, nitric oxide modulation and buffering capacities, plasma binding and transport of various substances, which may be particularly important in severe burns. Currently available data suggest that administration of exogenous albumin during the first 24 hours of resuscitation of severe burn patients may be associated with improved outcomes. Multi-centre randomized controlled trials with adequate power should be undertaken in burned patients.

NCT ID: NCT03379116 Completed - Severe Burn Clinical Trials

A Study on Nutrition Support in Adult Patients With Severe Burns

Start date: June 2, 2014
Phase: N/A
Study type: Observational

To delineate nutritional support in adults patients with severe burns to investigate associations between nutritional practice and clinical outcomes.

NCT ID: NCT03335137 Completed - Intensive Care Clinical Trials

Determining Drug Levels of Beta-lactam Antibiotics in Severe Burned Patients

MSBV
Start date: May 1, 2014
Phase: N/A
Study type: Observational

At antibiotic stewardship of the University Hospital of Schleswig-Holsten it was noticed that there are much less studies measuring drug levels in severe burned patients than are required. Especially, severe burned patient developing a capillary leak might show lower drug levels than patients without a capillary leak. To compare drug levels of beta-lactam antibiotics, it is the aim of this study to measure pharmacokinetics of Piperacillin/Tazobactam in ICU patients with and without severe burns.

NCT ID: NCT02638779 Completed - Septic Shock Clinical Trials

REAnimation Low Immune Status Markers

REALISM
Start date: December 11, 2015
Phase: N/A
Study type: Interventional

The fact that sepsis disrupts immune system homeostasis by inducing an initial cytokine storm, that participates to occurrence of organ failures and early death, followed by a compensatory anti-inflammatory response leading to immunosuppression, is now well established. This immunomodulating response results in a higher risk of secondary infections and is associated to 2/3 of deaths related to septic shocks. Follow up of patients' immune status with time is crucial to guide therapy management. Objective of REALISM project is to demonstrate existence of this immunosuppression phase, by providing strong epidemiologic data for septic shock patients, but also by extension to other situations of inflammatory aggressions like severe severe trauma or burns, or major surgery. This project will provide tools to predict occurrence of secondary infections and guide patient management by comparing innovating immunomonitoring tools to reference tests non already adapted to a routine patient management. Targeted populations are adult patients hospitalized for septic shock, severe trauma (including severe burn) or major surgery and healthy volunteers, whom blood samples will serve to validate reference intervals of the two reference tests.